RE:RE:RE:RE:RE:RE:RE:RE:Nothing like some 'leaks' on the FDA ResubmissionLooks like they made a few pages clearer (Nash bullet points are punchier) and added in the new sort1 data with decent explanations added. Hadn't realized the extent to which that breast cancer data was strong - last dose day 35 but tumor control went another 100 days so something must be going on in those cells.
Also added the immune cell infiltration as one of the valuable elements to the program. It has it's own box on the summary page now so they must view it as quite important going forward. All just models and still need to get past the lab experiments for anyone to bank on those findings. Like qwerty said, all clinical programs have great pre-clinical. I would add, some pre-clinical can find you partners!